Why the study?
Some patients develop thrombotic complications during clopidogrel and acetylsalicylic acid treatment due to resistance, necessitating a review of the causes and mechanisms to develop optimal management.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Highlights the need for a personalized approach to antiplatelet therapy by evaluating genetic and nongenetic factors that contribute to clopidogrel and acetylsalicylic acid resistance.
Cardiovascular diseases represent an important cause of mortality and morbidity in the world, and antiplatelet therapy is a cornerstone in their prophylaxis and treatment. Clopidogrel and acetylsalicylic acid are the most widely used antiplatelet agents as monotherapy or combination therapy for the secondary prophylaxis of major cardiovascular events. Recent studies have shown that some patients develop thrombotic complications during the treatment with clopidogrel and acetylsalicylic acid, due to the phenomenon of resistance. For these reasons, it is necessary to highlight the causes and mechanisms of resistance in order to develop an optimal management. Antiplatelet therapy requires a personalized approach to the patient, with the evaluation of genetic and nongenetic factors that may alter the response to clopidogrel and acetylsalicylic acid therapy.
No takes yet. Share an insight, caveat, or question.
Caracaş et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: